AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

AstraZeneca reported its largest quarterly revenue ever, as soaring sales of cancer drugs helped the drugmaker beat ...

AstraZeneca said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.